SLN360 + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Cardiovascular Diseases
Conditions
Cardiovascular Diseases, Atherosclerosis, Lipoprotein(a)
Trial Timeline
Dec 13, 2022 → Jul 1, 2024
NCT ID
NCT05537571About SLN360 + Placebo
SLN360 + Placebo is a phase 2 stage product being developed by Silence Therapeutics for Cardiovascular Diseases. The current trial status is completed. This product is registered under clinical trial identifier NCT05537571. Target conditions include Cardiovascular Diseases, Atherosclerosis, Lipoprotein(a).
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05537571 | Phase 2 | Completed |
Competing Products
20 competing products in Cardiovascular Diseases
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Dulaglutide + Placebo | Eli Lilly | Phase 3 | 77 |
| raloxifene + placebo | Eli Lilly | Phase 3 | 77 |
| Evacetrapib | Eli Lilly | Phase 1 | 33 |
| Orforglipron + Placebo | Eli Lilly | Phase 3 | 77 |
| Prasugrel (CS-747) + Clopidogrel | Eli Lilly | Phase 2 | 52 |
| Rosuvamibe + Monorova | Yuhan | Approved | 85 |
| Efficacy and safety of combination therapy of moderate-intensity statin and ezetimibe compared to high-intensity statin | Yuhan | Approved | 85 |
| Rosuvamibe + Monorova | Yuhan | Approved | 85 |
| Prasugrel (Crushed tablets) + Prasugrel (Integral tablets) | Daiichi Sankyo | Approved | 85 |
| Lexiscan | Astellas Pharma | Phase 2 | 52 |
| mirabegron + tamsulosin | Astellas Pharma | Phase 1 | 33 |
| TRC150094 | Torrent Pharmaceuticals | Phase 1/2 | 41 |
| Lorcaserin hydrochloride + Placebo | Eisai | Approved | 85 |
| Lepodisiran Sodium + Placebo | Eli Lilly | Phase 3 | 77 |
| Retatrutide + Placebo | Eli Lilly | Phase 3 | 77 |
| Empagliflozin + Placebos | Eli Lilly | Approved | 85 |
| Evacetrapib + Placebo | Eli Lilly | Phase 3 | 77 |
| Placebo + AZD0780 | AstraZeneca | Phase 2 | 52 |
| Risk of low dose aspirin discontinuation | AstraZeneca | Pre-clinical | 23 |
| Midazolam + AZD5718 | AstraZeneca | Phase 1 | 33 |
Other Products from Silence Therapeutics
SLN124 + PlaceboPhase 1/2
33
Atu027 & gemcitabine in lead in safety period + Atu027 & gemcitabine in treatment arm 1 + Atu027 & gemcitabine in treatment arm 2Phase 1/2
33
Atu027Phase 1
25
SLN124 + PlaceboPhase 1
25
SLN124 is a GalNAc conjugated double stranded fully modified siRNA. Sodium chloride 0.9% w/v is used as PlaceboPhase 1
25